Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 8/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.47 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29737942 | 1.00 | HCAR3 (0.48) | HCAR3LMNAMAPTALDH1A1PTGER4 | |
| SCHEMBL4589313 | 0.83 | ALDH1A1 (0.50) | LMNAMAPTALDH1A1PTGER4RAB9A | |
| SCHEMBL30080529 | 0.81 | MAPT (0.42) | LMNAMAPTRAB9APOLBMAPK1 | |
| SCHEMBL23753914 | 0.81 | MAPT (0.42) | LMNAMAPTRAB9APOLBMAPK1 | |
| SCHEMBL8246245 | 0.80 | MAPT (0.59) | HCAR3LMNAMAPTALDH1A1PTGER4 | |
| SCHEMBL30080478 | 0.80 | PRKCQ (0.47) | — | |
| SCHEMBL25210096 | 0.80 | PRKCQ (0.47) | — | |
| SCHEMBL23286239 | 0.79 | PTGER4 (0.44) | HCAR3MAPTALDH1A1PTGER4KDM4E | |
| Formic Acid SCHEMBL29111021 | 0.79 | LMNA (0.47) | HCAR3LMNAMAPTALDH1A1PTGER4 | |
| SCHEMBL25220286 | 0.77 | MAPT (0.39) | LMNAMAPTALDH1A1POLBHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023169436-A1 | BENZO BICYCLIC COMPOUND, AND PREPARATION METHOD AND APPLICATION THEREOF | 广州市联瑞制药有限公司 | 2023-09-14 | — | — | WO | disclosed |
| US-11702404-B2 | GLP-1R modulating compounds | GILEAD SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702404-B2 | GLP-1R modulating compounds | GILEAD SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230165846-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2023-06-01 | — | — | US | disclosed |
| CN-115697999-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-114630823-A | GLP-1R modulating compounds | 吉利德科学公司 | 2022-06-14 | — | — | CN | disclosed |
| WO-2021081207-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2021-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165846-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | HCAR3 272/4885LMNA 3213/4885MAPT 4096/4885 |
| US-11702404-B2 | GLP-1R modulating compounds | GLP1R, GIPR, GPR119 | HCAR3 258/4885LMNA 3309/4885MAPT 3314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.